Funding

Tikva Allocell

Singapore · Biotech

Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors

Visit tikvaallocell.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A$8MKantharos Capital — Role not disclosed

Investors

Kantharos CapitalSeries A

Coverage

Jul 22, 2026Tikva Allocell · Series A

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcestikvaallocell.com ↗